Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, double-blind, randomized, placebo-controlled trial of FavID (Id/KLH) [mitumprotimut T] and GM-CSF following CHOP/rituximab [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] as first-line therapy in subjects with high-intermediate and high-risk diffuse large B-cell lymphoma

Next Previous
X
Search
Trial Profile

Phase III, double-blind, randomized, placebo-controlled trial of FavID (Id/KLH) [mitumprotimut T] and GM-CSF following CHOP/rituximab [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] as first-line therapy in subjects with high-intermediate and high-risk diffuse large B-cell lymphoma

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitumprotimut T (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors MMRGlobal

    • Most Recent Events

    • 04 Jun 2007 Status changed from recruiting to suspended.
    • 06 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top